New epilepsy drug trial aims to reduce absence seizures
NCT ID NCT06769659
Summary
This study is testing whether an experimental medication called NPT 2042 can reduce the frequency and duration of absence seizures in people with genetic generalized epilepsy. Ten participants aged 16-75 will take either NPT 2042 or a placebo for a period, then switch after a two-week break, while researchers measure changes in seizure activity and quality of life. The goal is to see if this medication helps control seizures better than a dummy pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY, GENERALIZED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trials, Inc. (CTI)
RECRUITINGLittle Rock, Arkansas, 77205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.